Results 201 to 210 of about 1,830,783 (287)

Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing. [PDF]

Inflammopharmacology
Joodi SA, Nawwar DA, Rasheed NOA, Ibrahim WW, Sayed HM.   +4 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Repurposing Drugs – Repurposing Diseases

Repurposing Drugs – Repurposing Diseases
openaire   +1 more source

FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework. [PDF]

Acta Oncol
Abel E, Östling P, Hallersjö Hult E, Kulbacka K, Babacic H, Baan A, Carneiro A, De Petris L, Fagman H, Friesland S, Frisell O, Hellström M, Lindahl G, Steen Carlsson K, Tamborero D, Valachis A, Öhlund D, Lehtiö J, Rosenquist R, Edsjö A, FOCU.SE trial group.   +20 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Systems biology-based drug repurposing for neuroinflammation treatment in activated human microglia. [PDF]

Sci Rep
Cirinciani M, Germelli L, Da Pozzo E, Priami C, Martini C, Milazzo P.   +5 more
europepmc   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

BioMNEDR: mechanism-guided network embedding for drug repurposing. [PDF]

Brief Bioinform
Zeng Y, Wang L, Liu X.
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Drug repurposing to combat multidrug-resistant hookworm. [PDF]

Biol Open
McKean EL, Jackson CA, Dowd A, Hawdon JM, O'Halloran DM.   +4 more
europepmc   +1 more source